PMH56 INNOVATIONS IN COMBINING PATIENT REPORTED OUTCOMES WITH COGNITIVE TESTING DATA TO STREAMLINE AND LEVERAGE REAL-TIME DATA COLLECTION
Curry C PHT Corporation, Boston, MA, USA OBJECTIVES: Understand features of an electronic device that allow a marked improvement in the quality of collected data; the importance of improved data quality leading to enhanced patient safety and drug labeling; populations best suited for paired PRO and cognitive measurement technologies; important practical considerations for implementation in clinical trials including training and compliance; the potential for using real-time parallel data for adverse event safety monitoring. METHODS: This session discusses using ePRO and biometric technology for parallel data capture emphasizing advantages, disadvantages, execution, and ways to leverage these data. The session will review PRO and cognitive testing technologies, including comparisons of devices that combine physiological measures with a patient interface with systems that use separate PRO input and biometric devices. RESULTS: Assessing a treatment's ability to enhance or prohibit reduction of cognitive processing effi ciency is an emerging study in the pharmaceutical industry. Case studies examine how the use of cognitive function tests in combination with ePRO can enhance the data collection so drug effects otherwise unidentifi ed can be determined. The speaker will discuss the future of ePRO combined with biometric measurements as a standard of clinical research. CONCLUSIONS: Clinical trial endpoints can involve collection of physiologic and patient-reported outcome data; a combination of subjective and objective data. Electronic forms of information capture assure trial effi ciencies including edit checks and shorter time to database lock. ePRO provides time-stamped, legible and complete data from subjects. Biometric devices capture the physiological measurements. Typically, cognition data have been collected from patients separately from PRO data during clinical trials, increasing respondent burden and risk of error such as transposing manually entering data. The use of ePRO and biometric devices, evolution of data transmission technology, and greater technologic sophistication of consumers, provide an opportunity for parallel electronic data capture, simultaneously capturing and transmitting physiologic and PRO parameters in clinical studies.
PMH57 REVIEW OF CO-MORBIDITY OF EATING AND BODY DYSMORPHIC DISORDERS
Faragó E, Pakai A, Dér A, Oláh A, Boncz I, Németh K University of Pécs, Pécs, Hungary OBJECTIVES: Our intention was to investigate the prevalence of Eating Disorder and Body Dysmorphic Disorder in patients diaghnosed with depression, anxietay and borderline personality disorder by gender, using controll groups. METHODS: The reserach was 2009 at the Department of Phsyciatry of Szigetvár Hospital (Hungary). Eating Disorder Inventory was used. a self-made questionnaire aimed the body mass, body height and several demographic data. Inclusion criteria: ones between 18 and 50 years age, and according to BNO F32-F34 (depression), F41 (anxiety), F6030 (borderline personality disorder) diagnoses. Control group: participants with age between 18 and 50 years like that, who do not stand under a psychiatric treatment. The statistical analysis consisted of two sample T test, χ 2 -probe. RESULTS: The target group's number was 82, the control group 85. In the "The feeling of the insuffi ciency" (P < 0.001), "Interpersonal distrust" (P < 0.005), "Interoceptive consciousness" (P < 0.001) scales, the members of the control group from all three psychiatric patient groups reached a signifi cantly lower score away. In the "Bulimia" scale there was a signifi cantly lower score in the control group as well than the borderline in a group (P < 0.005), and here I found a signifi cant difference between the members of two psychiatric groups: the anxious group reached a lower score, compared with the borderline group (P < 0.001). CONCLUSIONS: The three psychiatric patient groups did not attain the threshold value onto one of the eating disturbances relevant scales neither There is not a direct, causal contact between the examined psychiatric clinical pictures. The men's higher result achieved on the "Bulimia" scale relates rather onto the binge eating disorder. The MMSE, CCS, FCS, BCS and DS were compared in their ability to explain variation in clinical outcomes, economicand other utilized resources, caregiver burden (Zarit Scale) and caregiver QoL (EQ-5D) using univariate (Pearson correlations) and multivariate (linear regression) analyses. Data on subjects and caregivers was obtained from multiple centres in Spain. RESULTS: In total 394 subjects, males and females aged 50 to 93 years old with mild cognitive impairment to severe dementia were included in this study. CCS, FCS, BCS and DS were moderately correlated with MMSE, with Pearson correlations ranging from −0.26 for BCS to −0.56 for CCS. These four clinical measures were also moderately correlated with medical costs, Zarit Scale and EQ-5D while MMSE was not. These measures also performed better in explaining variation in medical costs, Zarit Scale and caregivers' EQ-5D. MMSE performed better explaining variation in the number of concomitant conditions and caregiver time (hours per day). CONCLU-SIONS: The CCS, FCS, BCS and DS are better predictors in modelling AD progression on a higher number of variables including medical costs, caregivers' burden and caregivers QoL than the MMSE. Aripiprazole has been claimed to have a benefi cial effect on cognition with an emphasis on verbal functioning in schizophrenic patients. a prospective, multicenter, open-label study of Aripiprazole was set to evaluate the effect on quality of life, in relation to illness severity and cognitive functioning of a treatment with aripiprazole in schizophrenic patients. METHODS: A total of 363 schizophrenic patients from 18 to 65 years, treated with different typical and atypical antipsychotics or had no previous treatment, were switched to aripiprazole after a 2 week washout period. Quality of life was assessed by use of the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ) at 3 separate test moments in a 12 weeks period.
PMH58 MODELING PROGRESSION IN DEMENTIA: ASSESSING THE PERFORMANCE OF FIVE CLINICAL MEASURES IN SPANISH SUBJECTS AND CAREGIVERS

PMH59 EVALUATION OF THE EFFECT OF ARIPIPRAZOLE ON QUALITY OF LIFE IN PATIENTS
